Research graph
References from Molecular classification of endometrial cancer in fertility-sparing-treatment: toward a personalized clinical approach. Local targets link to admitted publications; unresolved targets remain external evidence.
Endometrial cancer
10.1016/s0140-6736(22)00323-3 · 2022 · External reference
NCCN guidelines® Insights: uterine neoplasms, version 3.2025
10.6004/jnccn.2025.0038 · 2025 · External reference
Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta-analysis
10.1002/cncr.33516 · 2021 · External reference
The game-changing impact of POLE mutations in oncology-a review from a gynecologic oncology perspective
10.3389/fonc.2024.1369189 · 2024 · External reference
Performance of molecular classification in predicting oncologic outcomes of fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer
10.1016/j.ijgc.2024.100016 · 2025 · External reference
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
10.1136/ijgc-2020-002230 · 2021 · External reference
Utility of molecular subtypes and genetic alterations for evaluating clinical outcomes in 1029 patients with endometrial cancer
10.1038/s41416-023-02203-3 · 2023 · External reference
Gene actionability according to the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) in No Specific Molecular Profile (NSMP) endometrial cancer
10.1016/j.esmoop.2025.105755 · 2025 · External reference
Classification of endometrial carcinoma: more than two types
10.1016/s1470-2045(13)70591-6 · 2014 · External reference
Impact of the FIGO 2023 staging system on the adjuvant treatment of endometrial cancer: A comparative analysis with FIGO 2009
10.3390/cancers17060934 · 2025 · External reference
ESGO/ESHRE/ESGE Guidelines for the fertility-sparing treatment of patients with endometrial carcinoma†,‡
10.1093/hropen/hoac057 · 2023 · External reference
Mismatch repair status influences response to fertility-sparing treatment of endometrial cancer
10.1016/j.ajog.2020.10.003 · 2021 · External reference
Application of the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) to patients conservatively treated: Outcomes from an institutional series
10.1016/j.ejogrb.2019.07.013 · 2019 · External reference
Turning ProMisE into practice: Predicting response in medically managed endometrial cancers via molecular classification
10.1016/j.ygyno.2020.06.032 · 2020 · External reference
Molecular classification in patients with endometrial cancer after fertility-preserving treatment: application of proMisE classifier and combination of prognostic evidence
10.3389/fonc.2022.810631 · 2022 · External reference
Fertility-sparing treatment in MSI-H/MMRd endometrial carcinoma or atypical endometrial hyperplasia: A systematic review and meta-analysis
10.1016/j.ejogrb.2024.09.006 · 2024 · External reference
Molecular subtyping in endometrial cancer: A promising strategy to guide fertility preservation
10.1016/j.ygyno.2023.11.006 · 2023 · External reference
Outcomes of fertility preservation treatments in patients with endometrial cancer with different molecular classifications based on an NGS panel
10.3389/fonc.2023.1282356 · 2023 · External reference
Efficacy of fertility-sparing treatment with LNG-IUS is associated with different ProMisE subtypes of endometrial carcinoma or atypical endometrial hyperplasia
10.3802/jgo.2024.35.e27 · 2024 · External reference
The prognostic impact of molecular classification in endometrial cancer that undergoes fertility-sparing treatment
10.1016/j.ijgc.2024.100024 · 2025 · External reference
The association of molecular classification with fertility-sparing treatment of atypical endometrial hyperplasia and endometrial cancer: a retrospective study
10.3389/fonc.2025.1506639 · 2025 · External reference
Prognostic impact of POLE exonuclease-domain mutations in endometrial cancer: A systematic review and meta-analysis
10.3390/cancers18040597 · 2026 · External reference
The clinicopathology and survival characteristics of patients with POLE proofreading mutations in endometrial carcinoma: A systematic review and meta-analysis
10.1371/journal.pone.0263585 · 2022 · External reference
Characteristics of molecular classification in 52 endometrial cancer and atypical hyperplasia patients receiving fertility-sparing treatment
10.1016/j.gocm.2023.01.006 · 2023 · External reference
Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer
10.1016/j.ajog.2021.05.007 · 2021 · External reference
Cytoplasmic progesterone and estradiol receptors in normal, hyperplastic, and carcinomatous endometria: therapeutic implications
10.1016/s0002-9378(15)33275-0 · 1981 · External reference
Molecular classification in fertility-sparing treatment of early-stage endometrial cancer: A potential tool for optimizing patient selection
10.1016/j.ygyno.2024.10.012 · 2024 · External reference
Potential of molecular classification to guide fertility-sparing management among young patients with endometrial cancer
10.1016/j.ygyno.2024.02.020 · 2024 · External reference
Molecular classification and fertility-sparing outcomes in endometrial cancer and atypical endometrial hyperplasia
10.17305/bb.2025.12445 · 2025 · External reference
Defective DNA mismatch repair influences expression of endometrial carcinoma biomarkers
10.1097/pgp.0000000000000193 · 2016 · External reference
Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma
10.1038/s41379-020-0501-8 · 2020 · External reference
Genomic and DNA methylomic factors associated with the efficacy of oral medroxyprogesterone acetate on endometrial neoplastic disease
10.1016/j.ygyno.2025.09.004 · 2025 · External reference
Inhibition of AKT with the orally active allosteric AKT inhibitor, MK-2206, sensitizes endometrial cancer cells to progestin
10.1371/journal.pone.0041593 · 2012 · External reference
Influence of AKT on progesterone action in endometrial diseases
10.1095/biolreprod.114.119255 · 2014 · External reference
Inhibiting the PI3K/Akt pathway reversed progestin resistance in endometrial cancer
10.1111/j.1349-7006.2010.01829.x · 2011 · External reference
RNA-seq and ATAC-seq analysis of CD163+ macrophage-induced progestin-insensitive endometrial cancer cells
10.1002/cam4.5396 · 2023 · External reference
Abnormal mismatch repair and other clinicopathologic predictors of poor response to progestin treatment in young women with endometrial complex atypical hyperplasia and well-differentiated endometrial adenocarcinoma: a consecutive case series
10.1111/1471-0528.14491 · 2017 · External reference
ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach
10.1093/annonc/mdz116 · 2019 · External reference
Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer
10.2217/fon-2020-0655 · 2021 · External reference
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study
10.1136/jitc-2021-003777 · 2022 · External reference
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial
10.1016/s1470-2045(18)30079-2 · 2018 · External reference
The association of progesterone receptor and abnormal p53 expression in endometrioid endometrial cancer
10.1200/jco.2023.41.16_suppl.e17611 · 2023 · External reference
Estrogen receptor, GATA-3, TTF-1, and KRAS in endometrial carcinoma of no specific molecular profile: prognostic or diagnostic markers
10.1016/j.modpat.2026.100978 · 2026 · External reference
The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification
10.3802/jgo.2019.30.e13 · 2019 · External reference
Akt-mediated phosphorylation and activation of estrogen receptor alpha is required for endometrial neoplastic transformation in Pten+/- mice
10.1158/0008-5472.can-05-4019 · 2006 · External reference
Prognostic significance of estrogen receptor expression and estrogen signaling in endometrial carcinomas of no specific molecular profile: A comprehensive molecular and pathologic analysis
10.1016/j.ygyno.2025.05.015 · 2025 · External reference
Prognostic role of immunohistochemical and molecular markers in no specific molecular profile endometrial cancer: a systematic review and meta-analysis
10.1016/j.ajog.2025.09.041 · 2026 · External reference
Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry
10.1038/s41416-023-02141-0 · 2023 · External reference
Grade and estrogen receptor expression identify a subset of no specific molecular profile endometrial carcinomas at a very low risk of disease-specific death
10.1016/j.modpat.2022.100085 · 2023 · External reference
Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis
10.1016/j.ygyno.2017.07.002 · 2017 · External reference
Should progesterone and estrogen receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis
10.1111/aogs.13586 · 2019 · External reference
Is the positivity of estrogen receptor or progesterone receptor different between type 1 and type 2 endometrial cancer
10.18632/oncotarget.13471 · 2017 · External reference
Systematic dissection of the mechanisms underlying progesterone receptor downregulation in endometrial cancer
10.18632/oncotarget.2392 · 2014 · External reference
ESGO–ESTRO–ESP guidelines for the management of patients with endometrial carcinoma: update 2025
10.1016/s1470-2045(25)00167-6 · 2025 · External reference
ARID1A regulates progesterone receptor expression in early endometrial endometrioid carcinoma pathogenesis
10.1016/j.modpat.2022.100045 · 2023 · External reference
Clinicopathological features and prognostic significance of CTNNB1 mutation in low-grade, early-stage endometrial endometrioid carcinoma
10.1007/s00428-021-03176-5 · 2021 · External reference
CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence
10.1038/modpathol.2017.15 · 2017 · External reference
Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles
10.1038/modpathol.2013.107 · 2014 · External reference
Navigating the future of fertility preservation: advanced predictive strategies for treatment outcomes of endometrial atypical hyperplasia and carcinoma
10.3802/jgo.2025.36.e123 · 2025 · External reference
Molecular prognosticators guiding fertility-sparing surgery in early-stage endometrial cancer: A comprehensive review
10.3390/cancers17223602 · 2025 · External reference
